INTEGRATING INDIVIDUAL PATIENT LEVEL RCT DATA WITH A COMPREHENSIVE DECISION ANALYTIC COST EFFECTIVENESS MODEL

Author(s)

Andrea Manca, PhD, Research Fellow1, Pedro Saramago, MSc, PhD student1, Martin Henriksson, PhD, Research Fellow21University of York, York, United Kingdom; 2 Linköping University, Linköping, Sweden

OBJECTIVES: Randomised controlled trials (RCTs) are the gold standard for demonstrating the efficacy of medical interventions. However, RCTs may be neither sufficient nor the most efficient vehicle to generate cost effectiveness (CE) evidence to inform healthcare resource allocation decisions. RCT evidence may (a) not be directly relevant to a given jurisdiction; (b) exclude relevant treatment strategies; (c) be too short in follow up. Comprehensive decision-analytic models (CDAMs) can help address the above challenges. These models are typically populated using summary measures, and often require strong distributional assumptions concerning their input parameters. We extend the use of CDAM, to accommodate and exploit the wealth of information contained in an individual patient-level dataset (IPD). METHODS: Using the UK RITA-3 trial, we show how to conduct a Bayesian analysis of IPD with the aim to (a) estimate input parameters to populate a CDAM and (b) inform probabilistic sensitivity analysis (PSA) to evaluate the decision problem. The proposed framework allows simultaneous estimation of a system of risk equations for specific events of interest, estimation of costs and quality of life implications related to the occurrence of these events, and PSA into a single CE model. Results are compared and contrasted with those from a standard two-stage approach, i.e. estimation of parameters through classical statistical inference, followed by PSA in a spreadsheet. RESULTS: Using IPD within the proposed analytical framework produced more accurate estimates than the standard two-stage approach in terms of posterior distributions of the incremental costs and QALYs. This resulted in a reduced decision uncertainty, as represented by the CE acceptability curve. CONCLUSIONS: CDAM based on IPD looks more promising and appropriate from the methodological point of view than standard (two-stage) modelling methods. This general analytical framework can be further extended to facilitate statistical evidence synthesis in the presence of multiple data sources.

Conference/Value in Health Info

2009-05, ISPOR 2009, Orlando, FL, USA

Value in Health, Vol. 12, No. 3 (May 2009)

Code

MO3

Topic

Methodological & Statistical Research

Topic Subcategory

Modeling and simulation

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×